In this podcast Dr Mairi McLean talks to Dr Christoph Gasche about his editors choice paper "Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice."

Full paper >> http://gut.bmj.com/content/64/12/1905.full

In this podcast Dr Mairi McLean talks to Dr Christoph Gasche about his editors choice paper "Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice." Full paper >> http://gut.bmj.com/content/64/12/1905.full

In this podcast Dr Mairi McLean talks to Dr Christoph Gasche about his editors choice paper "Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice."

Full paper &gt;&gt; http://gut.bmj.com/content/64/12/1905.full

Mesalazine and thymoquinone attenuate intestinal tumour development in mice

From June 2023, all our podcasts will move to https://gutbmj.podbean.com.
You can continue with your subscription on your favourite podcast App.

Gut is a leading international journal in gastroenterology and hepatology. It has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage of all areas in gastroenterology. Regular features include articles by leading authorities, reports on the latest treatments for diseases, reviews and commentaries. Subscribers to Gut also receive Frontline Gastroenterology (FG). 
The Gut Podcast discusses highlights from its issues monthly. Please subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Science

From June 2023, all our podcasts will move to https://gutbmj.podbean.com. You can continue with your subscription on your favourite podcast App. Gut is a leading international journal in gastroenterology and hepatology. It has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage of all areas in gastroenterology. Regular features include articles by leading authorities, reports on the latest treatments for diseases, reviews and commentaries. Subscribers to Gut also receive Frontline Gastroenterology (FG). The Gut Podcast discusses highlights from its issues monthly. Please subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Share Mesalazine and thymoquinone attenuate intestinal tumour development in mice

Sign up to save your podcasts

Mesalazine and thymoquinone attenuate intestinal tumour development in mice

Mesalazine and thymoquinone attenuate intestinal tumour development in mice